1
|
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2019; 30:1179. [PMID: 30624662 DOI: 10.1093/annonc/mdy535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
|
2
|
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23:1156-1164. [PMID: 21908496 DOI: 10.1093/annonc/mdr361] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized. PATIENTS AND METHODS Quantitative expression of PARP-1 protein was assayed by a specific immunohistochemical signal intensity scanning assay in a range of normal to malignant breast lesions, including a series of patients (N = 330) with operable breast cancer to correlate with clinicopathological factors and long-term outcome. RESULTS PARP-1 was overexpressed in about a third of ductal carcinoma in situ and infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P = 0.01), estrogen-negative tumors (P < 0.001) and triple-negative phenotype (P < 0.001). The hazard ratio (HR) for death in patients with PARP-1 overexpressing tumors was 7.24 (95% CI; 3.56-14.75). In a multivariate analysis, PARP-1 overexpression was an independent prognostic factor for both disease-free (HR 10.05; 95% CI 5.42-10.66) and overall survival (HR 1.82; 95% CI 1.32-2.52). CONCLUSIONS Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Animals
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/diagnosis
- Breast Neoplasms/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Cell Nucleus/metabolism
- Cell Nucleus/pathology
- Cells, Cultured
- Disease Progression
- Embryo, Mammalian
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Mice
- Mice, Knockout
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases/genetics
- Poly(ADP-ribose) Polymerases/metabolism
- Prognosis
- RNA, Small Interfering/pharmacology
- Survival Analysis
- Up-Regulation/drug effects
- Up-Regulation/genetics
Collapse
Affiliation(s)
- F Rojo
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - J García-Parra
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - S Zazo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - I Tusquets
- Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Ferrer-Lozano
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - S Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - P Eroles
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - C Chamizo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - S Servitja
- Medical Oncology Department, Hospital del Mar, Barcelona
| | | | - F Lobo
- Department of Oncology, IIS-Fundación Jiménez Díaz, Madrid
| | - B Bellosillo
- Department of Pathology, Hospital del Mar, Barcelona
| | - J M Corominas
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - J Yelamos
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Immunology Department, Hospital del Mar, Barcelona
| | - S Serrano
- Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - A Lluch
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia; Department of Medicine, Valencia Central University, Valencia, Spain
| | - A Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona.
| |
Collapse
|
3
|
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012; 23:1130-1137. [PMID: 21976387 DOI: 10.1093/annonc/mdr432] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. RESULTS Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. CONCLUSIONS Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
Collapse
Affiliation(s)
- J Cortes
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona.
| | - V Calvo
- Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid
| | - N Ramírez-Merino
- Department of Medical Oncology, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - J O'Shaughnessy
- Department of Medical Oncology, Baylor-Charles A. Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas
| | - A Brufsky
- Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh
| | - N Robert
- Department of Medical Oncology, Virginia Cancer Specialists, US Oncology, Fairfax, USA
| | - M Vidal
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - E Muñoz
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - J Perez
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - S Dawood
- Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
| | - C Saura
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - S Di Cosimo
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - A González-Martín
- Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | - M Bellet
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - O E Silva
- Department of Medical Oncology, University of Miami Leonard M. Miller School of Medicine, Miami, USA
| | - D Miles
- Department of Medical Oncology, Mount Vernon Cancer Centre, Middlesex, UK
| | - A Llombart
- Department of Medical Oncology, Arnau de Vilanova Hospital, Lérida, Spain
| | - J Baselga
- Department of Medical Oncology, Massachusetts General Hospital, Boston, USA
| |
Collapse
|